Variation in the Response of Clozapine Biotransformation Pathways in Human Hepatic Microsomes to CYP1A2 and CYP3A4-selective Inhibitors

Basic and Clinical Pharmacology and Toxicology - United States
doi 10.1111/bcpt.12933
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

The CYP3A4 Intron 6 C>T Polymorphism (CYP3A4*22) Is Associated With Reduced CYP3A4 Protein Level and Function in Human Liver Microsomes

Journal of Toxicological Sciences
MedicineToxicology
2013English

Utilization of Human Liver Microsomes to Explain Individual Differences in Paclitaxel Metabolism by CYP2C8 and CYP3A4

Journal of Pharmacological Sciences
Molecular MedicinePharmacology
2005English

A Clinical Study to Assess CYP1A2 and CYP3A4 Induction by AZD7325, a Selective GABAA Receptor Modulator - An in Vitro and in Vivo Comparison

British Journal of Clinical Pharmacology
Pharmacology
2012English

Inhibitors of Imipramine Metabolism by Human Liver Microsomes.

British Journal of Clinical Pharmacology
Pharmacology
1992English

The Phase I Biotransformation of the Potential Antileukotrienic Drug Quinlukast in Rat Microsomes and Hepatocytes

Collection of Czechoslovak Chemical Communications
2004English

Sorafenib N-Oxide Is an Inhibitor of Human Hepatic CYP3A4

AAPS Journal
Pharmaceutical Science
2019English

Stimulators and Inhibitors of Hepatic Porphyrin Formation in Human Sera

Journal of Clinical Investigation
Medicine
1974English

Unraveling the Molecular Pathways of DNA-methylation Inhibitors: Human Endogenous Retroviruses Induce the Innate Immune Response in Tumors

OncoImmunology
OncologyAllergyImmunology
2015English

Suppression of Hepatic CYP3A4 Expression and Activity by 3-Methylcholanthrene in Humanized PXR-CAR-CYP3A4/3A7 Mice

Drug Metabolism and Disposition
PharmacologyPharmaceutical Science
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy